MEDIUM confidence: 100% data completeness, but the composite (56) sits in the indecisive 30–70 range — strong-buy and short calls require a more decisive composite. What does confidence mean?
Technical context for active traders — derived from price, the 50/200-day moving averages, the 52-week range, and recent volume. Not part of the QScore.
Fama-French 5-factor (2×3) + Momentum, monthly OLS with Newey-West errors. Bars show signed factor betas; faded bars/figures aren't statistically significant.
AI classification of policy/regulatory sensitivity from the company's sector, industry, and business description. Exposure/sensitivity only — not a political opinion, a prediction of government action, or investment advice. As of 2026-07-10.
Dated events from the market calendar; the “also watch” items are AI-generated observations from QScoring data. Informational only — not investment advice, and dates can change.
Net buyback (repurchases less issuance) ÷ market cap, plus trailing dividend yield.
Net insider -$655K over 180 days (1 open-market buys, 1 sells). Insider buying is the informative signal; routine selling is normal.
Short interest, days-to-cover, and institutional-ownership change require a data-plan upgrade (not yet available).
Forward-return IC, quintile spread & hit rate publish on /performance as the tracking panel accrues enough no-look-ahead history.
Fewer than 3 analysts refreshed a price target in the last month, so no revision can be computed. Prior quarter: $285 avg across 8 analysts.
Buy-rated share 70% → 70% over ~3 months (+0pp).
| Quarter | Est. | Actual | Surprise |
|---|---|---|---|
| Aug 2026 | $1.99 | $2.09 | +5.0% |
| Apr 2026 | $1.90 | $1.97 | +3.7% |
| Feb 2026 | $1.94 | $2.01 | +3.6% |
| Oct 2025 | $1.76 | $1.89 | +7.4% |
| Jul 2025 | $1.69 | $1.78 | +5.3% |
| May 2025 | $1.69 | $1.75 | +3.6% |
| Feb 2025 | $1.85 | $1.87 | +1.1% |
| Oct 2024 | $1.62 | $1.66 | +2.5% |
| Metric (USD) | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Revenue | $5.5B— | $6.2B+10.9% | $6.6B+7.3% | $6.9B+5.2% | $7.4B+6.6% |
| EPS (dil.) | $4.25— | $5.01+17.9% | $5.67+13.2% | $5.93+4.6% | $6.40+7.9% |
| Free Cash Flow | $1.0B— | $1.0B-3.8% | $1.6B+58.3% | $1.7B+6.4% | $1.7B-1.8% |
| Gross Margin | 34.5% | 34.9%+0.4pp | 36.1%+1.3pp | 35.7%-0.5pp | 36.4%+0.7pp |
| Operating Margin | 23.6% | 24.4%+0.8pp | 25.9%+1.5pp | 25.6%-0.2pp | 26.2%+0.5pp |
| Net Margin | 17.9% | 18.9%+1.0pp | 19.9%+1.1pp | 19.8%-0.1pp | 20.0%+0.2pp |
Absolute figures with year-over-year change. Margins show the level with the change in percentage points (pp). “n/m” = not meaningful (prior ≤ 0); ⚠ marks a large percentage off a small base — read the dollar figure.
Working the DCF backward: holding the assumptions below, this is the free-cash-flow growth today's price implies over the next 10 years. It is a read on the price's embedded expectations — not a fair-value or target price.
The price implies FCF growth above the analyst consensus of 6.6%/yr (revenue basis).
Base free cash flow $1.7B (avg FY2023–FY2025; latest year $1.7B) · equity value $55.3B · levered FCF discounted at the cost of equity. Reverse DCF is illustrative, not advice.
The QScore of 56 for AMETEK indicates a neutral outlook, with the stock's short-term score slightly exceeding its long-term score. AMETEK scores high on risk and exhibits strong momentum, with a 12-month return of 30.9%, but is held back by its value category due to a P/E of 35.1 and P/B of 4.9, indicating it trades at a premium. The company's profitability is moderate, with an ROE of 14.5% and operating margin of 26.1%, while growth is steady, with revenue growth of 6.6% and EPS growth of 7.9%.